Alex Shalek

Biography
Alex K. Shalek is the Director of the Institute for Medical Engineering & Science (IMES) at the Massachusetts Institute of Technology (MIT), and the J. W. Kieckhefer Professor in IMES and the Department of Chemistry at MIT, as well as an Extramural Member of MIT's Koch Institute for Integrative Cancer Research. He is also an Institute Member of the Broad Institute, a Member of the Ragon Institute, and an Instructor in Health Sciences & Technology at Harvard Medical School. The multi-disciplinary research in his laboratory aims to create and implement broadly-applicable methods to study and engineer cellular responses in tissues, to drive biological discovery and improve prognostics, diagnostics, and therapeutics for autoimmune, infectious, and cancerous diseases. Shalek and his lab are best known for their work in single-cell and spatial genomics, and for studying a number of devastating, but difficult to study, human diseases with partners around the world.

Sarah Amalia Teichmann

Biography
Sarah completed her PhD at Cambridge's MRC Laboratory of Molecular Biology and was a Beit Memorial Fellow at UCL. She established her research group in 2001, discovering that protein assembly pathways are stereotypical and conserved. In 2016, she was appointed as the Head of the Cellular Genetics programme at the Wellcome Sanger Institute and co-founded the Human Cell Atlas initiative. From April 2024, she was appointed chair in Stem Cell Medicine at the University of Cambridge, within the Department of Medicine and the Cambridge Stem Cell Institute. Additionally, Sarah dedicates part of her time to GlaxoSmithKline, is a non-executive director of 10x Genomics, and has co-founded two startup companies. The Teichmann lab focuses on developing and applying cell atlas technologies to understand human tissue architecture, particularly examining how cellular diversity is generated in the immune system and during development.

---

Talk
TBC
TBC

Emma Lundberg

Biography
Dr. Emma Lundberg is Associate Professor of Bioengineering and Pathology at Stanford University, where she leads innovative research at the intersection of bioimaging, proteomics, and artificial intelligence. Her work focuses on modeling the spatiotemporal organization of the human proteome to uncover how protein localization influences cellular function and disease. Dr. Lundberg is an advocate for open science, with a passion for citizen science through computer games and computational challenges.

Satish Viswanath

Biography
Dr Viswanath holds appointments in the Departments of Pediatrics and Biomedical Engineering as well as a Research Biomedical Engineer at the Atlanta VA Medical Center. He has authored over 60 peer-reviewed journal publications, 130+ conference papers & abstracts, 1 book chapter, as well as delivered over 100 invited talks and panel discussions both in the US and abroad. He has 10 issued patents in the areas of medical image analysis, computer-aided diagnosis, and pattern recognition and has been elected to Senior Member in the National Academy of Inventors, the IEEE, and the SPIE. Recognition for his work includes the Fulbright Specialist Award, in addition to multiple awards from SIIM, SPIE, and Crain’s Cleveland Business. His research has received funding from federal and state agencies including the DOD/CDMRP, the VA, the NIH (NCI, NIBIB, NINR, NHLBI), as well as private foundations.

Shiva Nathan

Biography
Shiva Nathan is the founder of Onymos, a Silicon Valley-based software company building intelligent automation solutions for healthcare and life sciences. Before founding Onymos, Shiva was Head of Intuit's Platforms Services organization. He has also held technical leadership positions at Oracle and CA. These companies continue to leverage the products he helped define and build. He is an alumnus of BITS Pilani and UC Berkeleys Haas School of Business.

AI and Data Sciences Showcase:
Onymos
Onymos is building innovative automation software for the high-trust, high-stakes environments inside healthcare and life sciences. It helps organizations modernize their workflows and unlock the value of unstructured data without ever compromising security, compliance, or control.

Rebecca Critchley-Thorne

Biography
Dr. Rebecca Critchley-Thorne joined Castle Biosciences in December 2021 as Vice President, RD, Spatialomics and GI, as part of the acquisition of Cernostics Inc., where she was Co-Founder and Chief Scientific Officer. She led the development of the Tissue Cypher computational pathology platform as well as the Tissue Cypher Barretts Esophagus test and its supporting clinical studies. She currently oversees RD for Castles commercially available tests and pipeline activities. She completed training as a postdoctoral fellow at Stanford University, where she focused on highly multiplexed analysis of biomarkers to understand mechanisms of immune dysfunction in various cancer types. She completed doctoral work in cancer immunotherapy at Imperial College and Cancer Research UK in London, UK, and earned a B. S. (Hons) degree in Pharmacology from the University of Sheffield, UK. Dr. Critchley-Thorne is the author of many medical and scientific publications, a principal investigator on NIH-funded research studies, and an inventor on several of Castle's patents.

Garry Nolan

Biography
Dr. Garry P. Nolan is the Rachford and Carlota A. Harris Professor in the Department of Pathology at Stanford University School of Medicine. Trained with Leonard Herzenberg (Ph.D.) and Nobel laureate David Baltimore (postdoc), he is known for cloning and characterizing NF-κB p65/RelA and developing rapid retroviral production systems. Author of over 350 papers and holder of 50 U.S. patents, he has received multiple honors, including the Teal Innovator Award, FDA BAAA, and Nature Publishing Group’s Outstanding Research Achievement. His research spans hematopoiesis, cancer, autoimmunity, inflammation, and systems immunology, with a focus on single-cell analysis technologies such as CyTOF, MIBI, and CODEX. Dr. Nolan has founded or co-founded multiple biotech companies, with several acquired by industry leaders. His current work applies high-dimensional imaging and cytometry to deepen understanding of immune function, pathogen response, and cancer biology, aiming to improve disease management and clinical outcomes.

Maximilian Strauss

Biography
Maximilian Strauss works at the intersection of artificial intelligence and mass-spectrometry proteomics, where he co-founded and drives the technology behind a high-throughput spatial proteomics platform that turns human tissue into AI-ready molecular data. His focus is building the data engine and frontier AI models that learn across tissue images, the human proteome and drugs — working toward foundation models of biology — so medicines can be matched to the patients most likely to benefit. He trained in mechanical engineering at the Technical University of Munich, with thesis research at Harvard's Wyss Institute, before doctoral research in physics on super-resolution imaging in Ralf Jungmann's lab at the Max Planck Institute. He completed a postdoc with Matthias Mann in Munich and Copenhagen and led bioinformatics at OmicEra Diagnostics (later acquired by Exact Sciences). He has also held a faculty position as an Assistant Professor in bioinformatics at the University of Copenhagen.

---

Talk
Molecular Intelligence: From Tissue to Treatment
The industry designs molecules; Resolute discovers who they work for. Going beyond DNA and RNA into the human spatial proteome, we combine computational pathology with mass spectrometry to learn the relationship between tissue and the proteome — building foundation models for trial selection and the next generation of precision medicine.

Aviv Regev

Biography
Dr Regev joined Genentech in August 2020 as Head and Executive Vice President, Genentech Research and Early Development. In this role, she is responsible for the management of all aspects of gRED’s drug discovery and drug development activities. In addition, Dr Regev is a member of the Genentech Executive Committee and Board of Directors, and a member of the expanded Corporate Executive Committee for Roche. She also run an active research lab focused on developing and applying experimental methods and computational algorithms to decipher intra- and intercellular circuits in cells in tissues. Prior to Genentech, Dr. Regev served as Chair of the Faculty, Core Institute Member (currently on leave), Founding Director of the Klarman Cell Observatory, and member of the Executive Leadership Team of the Broad Institute of MIT and Harvard, as well as Professor of Biology at MIT (currently on leave) and Investigator at the Howard Hughes Medical Institute. She is a founding co-chair of the Human Cell Atlas.

Serge Saxonov

Biography
Serge Saxonov is the co-founder and CEO of 10x Genomics, a leader in singlecell and spatial biology. 10xs mission is to accelerate the mastery ofbiology to advance human health. Under Serges leadership, 10x hasdelivered groundbreaking products that have transformed how researchersexplore biology. These tools and technologies have been cited in more than10,000 high-impact publications and have enabled discoveries across nearlyevery area of life sciences.As a scientist, inventor and entrepreneur, Serge guided 10x from anearly-stage startup through one of the fastest revenue ramps in theindustrys history to its public debut on Nasdaq (TXG), and has since ledthe companys continued growth and innovation. Before 10x, he was part ofthe founding team at 23andme, where he pioneered the companys coretechnology and product concepts, and later served as Vice President ofApplications at QuantaLife, which was acquired by Bio-Rad.Serges leadership and entrepreneurship have been recognized by GoldmanSachs, which named him one of its 100 Most Intriguing Entrepreneurs in2016, and by the San Francisco Business Times, which honored him as one ofthe Bay Areas Most Admired CEOs in 2021. He earned his A.B. in AppliedMathematics from Harvard College and his Ph.D. in Biomedical Informaticsfrom Stanford University.

Fei Chen

Biography
Fei Chen is a core institute member at the Broad Institute of MIT and Harvard and an associate professor in the Department of Stem Cell and Regenerative Biology at Harvard University. Chen’s laboratory is building tools that bridge single-cell genomics with space and time, to enable discoveries of where cell types are localized within intact tissues, as well as when relevant transcriptional modules are active. To do this, the lab is developing novel experimental and computational technologies at the intersection of microscopy, genomics, and synthetic biology. His group is applying these tools to learn organizational principles governing tissue development and cellular mechanisms of disorganization during injury and disease. During his doctoral research, Chen co-invented expansion microscopy, a breakthrough technique that allows for super-resolution imaging of biological samples with conventional light microscopes. As an independent fellow at the Broad Institute, he led a group that continued to pioneer novel tools at the intersection of genomics and microscopy to uniquely illuminate biological pathways and function. These include Slide-seq, a novel technology platform for performing genomic measurements of DNA and RNA within tissues with near-single-cell resolution, and in situ genome sequencing, which allows for de novo sequencing of DNA within cells and tissues. Chen obtained his Ph.D. in biological engineering from the Massachusetts Institute of Technology, where he worked with Ed Boyden. Chen was a Schmidt Fellow at the Broad Institute. His awards include the National Institutes of Health Director’s Early Independence Award, the Searle Scholars Award, the Burroughs Wellcome CASI Award, the Allen Distinguished Investigator Award, and a Merkin Institute Fellowship.

Kevin Wei

Biography
Dr. Kevin Wei is an Assistant Professor of Medicine at Harvard Medical School and an associate rheumatologist at Brigham and Women’s Hospital. Dr. Wei received his Bachelor of Science in biology from Duke University and his medical as well as doctoral degrees from Stanford University School of Medicine. He completed his internal medicine residency followed by a rheumatology fellowship at Brigham and Women’s Hospital. He is a member of the NIH’s Accelerating Medicines Partnership (AMP-RA/SLE) consortium. Dr. Wei is co-Director of the BWH Center for Cellular Profiling and Associate Director of the Harvard Medical School/BWH Joint Biology Consortium Cellular Systems Core. Dr. Wei’s research focuses on identifying novel cellular and molecular therapeutic targets in inflammatory diseases using single-cell and spatial technologies.

---

Talk
Towards Precision Medicine in Chronic Inflammatory Diseases.
n/a